Replimune Group Stock Forecast, Price & News

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Replimune Group in the last year. There are currently 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Replimune Group stock.
View analyst ratings for Replimune Group or view top-rated stocks.

Wall Street analysts have given Replimune Group a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Replimune Group wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Replimune Group is scheduled to release its next quarterly earnings announcement on Wednesday, June 2nd 2021.
View our earnings forecast for Replimune Group.

Replimune Group, Inc. (NASDAQ:REPL) announced its earnings results on Thursday, February, 4th. The company reported ($0.44) earnings per share for the quarter, missing analysts' consensus estimates of ($0.41) by $0.03.
View Replimune Group's earnings history.

Replimune Group's stock was trading at $11.93 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, REPL stock has increased by 155.7% and is now trading at $30.50.
View which stocks have been most impacted by COVID-19.

9 Wall Street analysts have issued 1 year target prices for Replimune Group's shares. Their forecasts range from $48.00 to $67.00. On average, they anticipate Replimune Group's stock price to reach $56.00 in the next year. This suggests a possible upside of 83.6% from the stock's current price.
View analysts' price targets for Replimune Group or view top-rated stocks among Wall Street analysts.

Some companies that are related to Replimune Group include Beam Therapeutics (BEAM), China Biologic Products (CBPO), Allogene Therapeutics (ALLO), Iovance Biotherapeutics (IOVA), Ablynx (ABLYF), SpringWorks Therapeutics (SWTX), NanoString Technologies (NSTG), Relay Therapeutics (RLAY), Revolution Medicines (RVMD), Editas Medicine (EDIT), Bavarian Nordic A/S (BVNRY), Vericel (VCEL), Sorrento Therapeutics (SRNE), bluebird bio (BLUE) and Rubius Therapeutics (RUBY).
View all of REPL's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Replimune Group investors own include Peabody Energy (BTU), Myovant Sciences (MYOV), (BTUUQ) (BTUUQ), AVEO Pharmaceuticals (AVEO), Fate Therapeutics (FATE), Immunomedics (IMMU), Pfizer (PFE), SCYNEXIS (SCYX), Exelixis (EXEL) and Fulcrum Therapeutics (FULC).

(REPL) raised $100 million in an initial public offering on Friday, July 20th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO.

Replimune Group trades on the NASDAQ under the ticker symbol "REPL."

Shares of REPL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of REPL stock can currently be purchased for approximately $30.50.

Replimune Group has a market capitalization of $1.42 billion. The company earns $-52,630,000.00 in net income (profit) each year or ($1.54) on an earnings per share basis.

Replimune Group employs 122 workers across the globe.

The official website for Replimune Group is www.replimune.com.

Replimune Group is headquartered at 500 Unicorn Park, WOBURN MA, 01801.

Replimune Group's mailing address is 500 Unicorn Park, WOBURN MA, 01801. The company can be reached via phone at 781-222-9600 or via email at [email protected]